152 related articles for article (PubMed ID: 2095310)
1. K(+)-channel openers: new antihypertensive drugs?
Haeusler G
Clin Physiol Biochem; 1990; 8 Suppl 2():46-56. PubMed ID: 2095310
[TBL] [Abstract][Full Text] [Related]
2. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
Nielsen-Kudsk JE
Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effects of cromakalim and pinacidil on mechanical activity and 86Rb efflux in dog coronary arteries.
Masuzawa K; Asano M; Matsuda T; Imaizumi Y; Watanabe M
J Pharmacol Exp Ther; 1990 May; 253(2):586-93. PubMed ID: 2160002
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the vasodilatation by the K+ channel openers: cromakalim and pinacidil.
Rhim BY; Lee WS; Hong KW
Jpn J Pharmacol; 1992; 58 Suppl 2():335P. PubMed ID: 1507584
[No Abstract] [Full Text] [Related]
5. [Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
Satoh K
Nihon Rinsho; 1993 May; 51(5):1293-8. PubMed ID: 8331797
[TBL] [Abstract][Full Text] [Related]
6. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
Longman SD; Clapham JC; Wilson C; Hamilton TC
J Cardiovasc Pharmacol; 1988; 12(5):535-42. PubMed ID: 2468052
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia.
Grover GJ
J Cardiovasc Pharmacol; 1994; 24 Suppl 4():S18-27. PubMed ID: 7898104
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of the potassium channel opening activity of GYKI-12743 by 86Rb+ efflux studies.
Bakonyi A; Horváth EJ
Acta Physiol Hung; 1994; 82(4):295-300. PubMed ID: 7785439
[TBL] [Abstract][Full Text] [Related]
9. Modulation of intracellular calcium by potassium channel openers in vascular muscle.
Erne P; Hermsmeyer K
Naunyn Schmiedebergs Arch Pharmacol; 1991 Dec; 344(6):706-15. PubMed ID: 1775202
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of potassium channel openers.
Andersson KE
Pharmacol Toxicol; 1992 Apr; 70(4):244-54. PubMed ID: 1535127
[TBL] [Abstract][Full Text] [Related]
11. Effect of three novel K+ channel openers, cromakalim, pinacidil and nicorandil on allergic reaction and experimental asthma.
Nagai H; Kitagaki K; Goto S; Suda H; Koda A
Jpn J Pharmacol; 1991 May; 56(1):13-21. PubMed ID: 1831870
[TBL] [Abstract][Full Text] [Related]
12. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG
J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775
[TBL] [Abstract][Full Text] [Related]
13. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
Tosaki A; Szerdahelyi P; Engelman RM; Das DK
J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide.
Quast U; Cook NS
J Pharmacol Exp Ther; 1989 Jul; 250(1):261-71. PubMed ID: 2501478
[TBL] [Abstract][Full Text] [Related]
15. Potassium channels and human corporeal smooth muscle cell tone: diabetes and relaxation of human corpus cavernosum smooth muscle by adenosine triphosphate sensitive potassium channel openers.
Venkateswarlu K; Giraldi A; Zhao W; Wang HZ; Melman A; Spektor M; Christ GJ
J Urol; 2002 Jul; 168(1):355-61. PubMed ID: 12050569
[TBL] [Abstract][Full Text] [Related]
16. Cardiohemodynamic effects of cromakalim and pinacidil, potassium-channel openers, in the dog, special reference to venous return.
Gotanda K; Yokoyama H; Satoh K; Taira N
Cardiovasc Drugs Ther; 1989 Aug; 3(4):507-15. PubMed ID: 2488102
[TBL] [Abstract][Full Text] [Related]
17. Alterations by glyburide of effects of BRL 34915 and P 1060 on contraction, 86Rb efflux and the maxi-K+ channel in rat portal vein.
Hu SL; Kim HS; Okolie P; Weiss GB
J Pharmacol Exp Ther; 1990 May; 253(2):771-7. PubMed ID: 2110977
[TBL] [Abstract][Full Text] [Related]
18. The effect of intracavernous injection of potassium channel openers in monkeys and dogs.
Trigo-Rocha F; Donatucci CF; Hsu GL; Nunes L; Lue TF; Tanagho EA
Int J Impot Res; 1995 Mar; 7(1):41-8. PubMed ID: 7670592
[TBL] [Abstract][Full Text] [Related]
19. [Potassium channel activators. Perspectives in the treatment of arterial hypertension].
Giudicelli JF; Richer C; Berdeaux A
Presse Med; 1991 Jan; 20(2):75-81. PubMed ID: 1825708
[TBL] [Abstract][Full Text] [Related]
20. [Potassium channel openers. A new possible therapeutic principle in several diseases].
Drottning P; Christensen H; Storstein L
Tidsskr Nor Laegeforen; 1994 Feb; 114(4):450-3. PubMed ID: 8009483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
